Longevity News

A blinded, prospective benchmark of in silico antibody discovery anchored to experimental affinity and developability

Source: Nature - Biotechnology • Published: 19 Aug 2026, 00:00

A blinded, prospective benchmark of in silico antibody discovery anchored to experimental affinity and developability

Investigates a blinded, prospective benchmark where forty-nine in silico antibody design submissions were evaluated against experimental affinity and developability data to test computational prediction performance.

Key Takeaways
  • Amino acid sequence is not a functionally readable ‘language’
  • Exceptions are the heavy and light third complementarity-determining regions (CDR3s)
  • Unlike natural language, the statistically dominant token is often not optimal for affinity improvement 11
Read Original Source

Continue exploring

Related longevity signals

Frontiers - HealthAnti-CD6 monoclonal antibody UMCD6 induces CD6 internalization, remodels costimulatory receptor availability, and modulates CD4+ T-cell activationExamines how an anti-CD6 monoclonal antibody triggers CD6 internalization and alters costimulatory receptor availability to reshape CD4+ T-cell activation.Fight Aging!Antibody-Phototherapy Selectively Targets Harmful Oral Bacteria to Treat PeriodontitisA write-up about a targeted phototherapy approach for selectively removing a keystone oral bacterium to rebalance the mouth’s microbiome and treat gum disease, inviting readers to learn what kind of study and methods are described.Nature - BiotechnologyDroplet digital PCR reveals that transgene copy number determines lifespan in SOD1G93A ALS miceA methods-focused research article examining how a precise DNA quantification technique maps transgene copy variation to disease trajectory in an ALS mouse model.Frontiers - HealthAdjunctive traditional Chinese medicine for ischemic stroke: a systematic review with structured narrative synthesis and GRADE assessment of randomized controlled trialsA structured systematic review evaluates randomized trials of specific traditional Chinese medicine formulations used alongside standard care for ischemic stroke across acute, recovery, and prevention stages.